ARTICLE | Clinical News

Tanezumab: FDA hold

July 26, 2010 7:00 AM UTC

Pfizer suspended the chronic low back pain and painful DPN programs for tanezumab after FDA placed the Phase II programs on clinical hold. Last month, FDA placed a clinical hold on the osteoarthritis (OA) program due to reports of worsening OA leading to joint replacement in tanezumab-treated patients (see BioCentury, June 28). Pfizer said it has submitted additional information to FDA on the implications of these events in other tanezumab indications. ...